Isomoto H, Furusu H, Ohnita K, Wen CY, Inoue K, Kohno S. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol 2005; 11(11): 1629-1633 [PMID: 15786539 DOI: 10.3748/wjg.v11.i11.1629]
Corresponding Author of This Article
Dr. Hajime Isomoto, Gastrointestinal Unit, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Jackson 706, 55 Fruit Street, Boston, MA 02114, USA. hajimei2002@yahoo.co.jp
Article-Type of This Article
Brief Reports
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 21, 2005; 11(11): 1629-1633 Published online Mar 21, 2005. doi: 10.3748/wjg.v11.i11.1629
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin
Hajime Isomoto, Hisashi Furusu, Ken Ohnita, Shigeru Kohno, Second Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto 1-7-1, Nagasaki, Japan
Chun-Yang Wen, Department of Molecular Pathology, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Sakamoto 12-4, Nagasaki, Japan
Chun-Yang Wen, Department of Digestive Disease, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu Province, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Hajime Isomoto, Gastrointestinal Unit, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Jackson 706, 55 Fruit Street, Boston, MA 02114, USA. hajimei2002@yahoo.co.jp
Telephone: +1-617-7248977 Fax: +1-617-7262373
Received: August 14, 2004 Revised: August 15, 2004 Accepted: November 23, 2004 Published online: March 21, 2005
Abstract
AIM: The mucoprotective agents, sofalcone and polaprezinc have anti-Helicobacter pylori (H pylori) activities. We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection.
METHODS: One hundred and sixty-five consecutive outpatients with peptic ulcer and H pylori infection were randomly assigned to one of the following three groups and medicated for 7 d. Group A: triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily). Group B: sofalcone (100 mg thrice daily) plus the triple therapy. Group C: polaprezinc (150 mg twice daily) plus the triple therapy. Eradication was considered successful if 13C-urea breath test was negative at least 4 wk after cessation of eradication regimens or successive famotidine in the cases of active peptic ulcer.
RESULTS: On intention-to-treat basis, H pylori cure was achieved in 43 of 55 (78.2%) patients, 47 of 54 (87.0%) and 45 of 56 (80.4%) for the groups A, B and C respectively. Using per protocol analysis, the eradication rates were 81.1% (43/53), 94.0% (47/50) and 84.9% (45/53) respectively. There was a significant difference in the cure rates between group A and B. Adverse events occurred in 10, 12 and 11 patients, from groups A, B and C respectively, but the events were generally mild.
CONCLUSION: The addition of sofalcone, but not polaprezinc, significantly increased the cure rate of H pylori infection when combined with the rabeprazole-amoxicillin-clarithromycin regimen.
Citation: Isomoto H, Furusu H, Ohnita K, Wen CY, Inoue K, Kohno S. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol 2005; 11(11): 1629-1633
Helicobacter pylori (H pylori) causes type B chronic gastritis and plays a critical role in the pathogenesis of peptic ulceration[1,2]. Eradication of H pylori infection facilitates ulcer healing and prevents recurrence[3-5]. In the quest for optimal choice of drugs, dosage and duration, various therapeutic regimens have been studied extensively during the past few years. Among these, short-term low-dose triple therapy, comprising of one proton pump inhibitor and two antimicrobials from the choice of clarithromycin, amoxicillin and metronidazole, is currently considered the gold standard regimen[6,7]. The new proton pump inhibitor-based triple therapies provide high eradication rates, which are generally more than 80%. In fact, we reported that a 7-d course of rabeprazole, a novel potent proton pump inhibitor, 10 mg b.d. plus amoxicillin 750 mg b.d. and clarithromycin 200 mg b.d. showed satisfactory results[8]. Nevertheless, there are still some disadvantages to be addressed such as drug resistance when considering the PPI-based triple therapies[9-13]. With the rising prevalence of resistance of H pylori to metronidazole or clarithromycin, failure rates of the PPI-based regimens are expected to increase[12,13].
A variety of gastric mucoprotective agents have been used as anti-ulcer drugs, usually in combination with antacids, in the upper gastrointestinal tract[14]. Among these, rebamipide, ecabet sodium, sofalcone, polaprezinc, plaunotol and sucralfate are uncomplicated by drug resistance and have anti-H pylori activities[14-21]. Therefore, the theoretical rationale for adding such mucoprotective drugs to ordinary eradication regimens is that these may meet demands of improved treatment outcome without the development of resistance.
There are several reports on the additive effects of mucoprotective drugs in eradication regimens, but most of the study designs were not randomized and the sample sizes were limited[14,22-27]. In addition, there is little information on the most effective mucoprotective drugs. This prospective, randomized study was designed to determine whether the inclusion of sofalcone or polaprezinc increases the cure rate of H pylori infection when combined with the rabeprazole-amoxicillin-clarithromycin therapy.
MATERIALS AND METHODS
Patients
The present study was designed as a prospective, open, randomized and controlled trial, which was performed between January 1999 and December 2002. The study was conducted according to Good Clinical Practice and the Declaration of Helsinki. All patients gave informed consent prior to their inclusion in the study.
The patient population comprised 165 consecutive outpatients with peptic ulcer and H pylori infection. Exclusion criteria were: age <18 years, pregnancy or lactation, severe concomitant diseases, previous medications effective against H pylori such as bismuth compounds, proton pump inhibitors, or antibiotics during the last 3 mo, alcohol abuse, drug addiction, chronic corticosteroid or nonsteroidal anti-inflammatory drug use, and previous gastroduodenal surgery. Information on alcohol intake and smoking habits was obtained at entry into the study. Ex-smokers and social drinkers were considered as nonsmokers and nondrinkers respectively.
The presence of H pylori was confirmed by serology (anti-H pylori Immunoglobulin G antibody, HEL-p TEST, AMRAD Co., Melbourne, Australia), rapid urease test (Helicocheck, Otsuka Pharmaceutical Co., Tokushima, Japan) and histology (Giemsa staining) using two biopsy specimens obtained during endoscopy from each the antrum (within 2 cm of the pyloric ring) and the corpus (along the greater curvature). Patients were considered to be infected with H pylori when at least two of these examinations gave positive results. Patients were classified as H pylori-negative when all test results were negative. Patients who had only one positive result were not included.
Clinical trial
The enrolled patients were randomized by drawing a sealed envelope that contained pre-assigned treatment instructions. They were allocated to one of the following three groups and were medicated for 7 d: group A, which received rabeprazole 10 mg b.d., clarithromycin 200 mg b.d. and amoxicillin 750 mg b.d.; group B, which received sofalcone [2’-carboxymethyl 4, 4’-bis (3-methyl-2-butenyloxy) chalcone] 100 mg t.i.d., in combination with rabeprazole 10 mg b.d., clarithromycin 200 mg b.d. and amoxicillin 750 mg b.d.; group C, polaprezinc, zinc L-carnosine [N- -aminopropionyl-L-histidinato zinc (II) 150 mg b.d. in combination with rabeprazole 10 mg b.d., clarithromycin 200 mg b.d. and amoxicillin 750 mg b.d. Both the sofalcone and polaprezinc were prescribed as the standard daily dosage. If an active ulcer (defined as a circumscribed break in the mucosa measuring at least 5 mm in diameter with apparent depth and covered with an exudates[30]) was found at baseline endoscopy, it was treated with an H2-receptor antagonist (famotidine 20 mg twice daily) for 4 wk after the eradication therapy. In cases of peptic ulcer scar, no other ulcer healing drugs were provided throughout the study. Participants returned at the conclusion of therapy for interview regarding adverse events. Compliance with medication was checked immediately after stopping treatment by counting the number of returned pills. Four weeks after cessation of eradication therapy, repeat endoscopy was performed to assess H pylori status by the rapid urease test and histology as before treatment. In patients with peptic ulcer in the active phase, the endoscopy-based tests were performed 4 wk after stopping famotidine (8 wk after the completion of eradication). Ulcer healing (defined as complete re-epithelialization) was assessed at the time of repeat endoscopy. Furthermore, we adopted the 13C-urea breath test for the evaluation of H pylori cure 4 wk or longer after completion of treatment. In patients with active peptic ulcer, the 13C-urea breath test was performed 4 wk or longer after completion of the ulcer treatment with famotidine (at least 8 wk after completion of the eradication therapy). The urea breath test was performed as described previously[31]. Briefly, 13C-urea at 100 mg (Otsuka Pharmaceutical Co.) was dissolved in 100 mL of water. The test solution was ingested while in the sitting position, followed immediately by mouth rinsing. The patient was subsequently placed in the left decubitus position for 5 min and then in the sitting position for 15 min. Breath samples were collected, at baseline and 20 min after dosing and then analyzed using an isotope-selected nondispersive infrared spectrometer; UBiT-IR200 (Otsuka Electronics Co., Hirakata, Japan). The cut-off value was set at 2.5%; eradication of H pylori was considered successful if all test results were negative[31].
Statistical analysis
H pylori cure rate was evaluated by intention-to-treat (ITT) and per protocol (PP) analyses. ITT analysis included all enrolled patients and patients who dropped out were regarded as treatment failures. PP analysis included all patients who took at least 80% of each study medication as prescribed and returned for assessment of H pylori cure[24]. The cure rate was calculated together with 95% confidence intervals (CI). Statistical analyses were performed using the χ2, Fisher’s exact and Student’s t-tests, as appropriate. A P value less than 0.05 was accepted as statistically significant.
RESULTS
The enrolled patients comprised 125 men and 40 women, with a mean age of 46 years (range, 21-73). They included 101 patients with gastric ulcer, 59 with duodenal ulcer and 5 with gastroduodenal ulcer. The peptic ulcer was in the active phase in 87 patients. The baseline characteristics of the study population are listed in Table 1. The three treatment groups were well matched for gender, age, body weight, alcohol intake, smoking habits and baseline diagnosis. Of the 165 patients enrolled in this study, 4 patients (1 from group A, 1 from group B and 2 from group C) were lost to follow-up. Furthermore, 5 patients (1 from group A, 3 from group B and 1 from group C) were excluded from PP analysis as their compliance was less than 80%, leaving 156 patients for PP analysis.
Table 2 shows ITT and PP H pylori eradication rates in each treatment group. In the ITT analysis, there were no significant differences in H pylori cure rates among the three groups, while the PP-based eradication rate in group B was significantly higher than that in group A (P<0.05). Background characteristics including age, gender, body weight, current tobacco use, alcohol intake and baseline diagnosis did not affect treatment outcome.
Table 2 Intention-to-treat and per protocol cure rates of H pylori infection.
At the following endoscopy, ulcer healing was comparably observed in 24 out of 27 patients in group A (88.9%, 95%CI = 76.2-100%), 28 out of 32 in group B (87.5%, 95%CI = 75.4-99.6%) and 24 out of 28 (85.7%, 95%CI = 71.9-99.5%).
Adverse events were noted in 10 patients from group A, 12 from group B and 11 from group C. These included diarrhea or soft stools, heartburn, nausea and skin rash (Table 3), and resulted in discontinuation of treatment in one patient from group B due to skin rash. Overall, the adverse events were mild and self-limited. No significant differences in the incidence and proportion of adverse events were observed among the three groups.
Table 3 Adverse events in the three treatment groups (n, %).
The generally assumed mechanisms of action of mucoprotective agents involve up-regulation of gastric mucosal defense during the process of recovery from mucosal injury[14]. Some of these drugs are also reported to have anti-H pylori activities through different mechanisms[14-21]. Amidst this background, a series of trials have been carried out in which such mucoprotective agents were added to the original dual or triple therapy regimens in an attempt to improve the efficacy[22-27]. The meta-analysis study of Hojo et al[14], supported the view that the eradication rates can be enhanced by adding mucoprotective agents to dual therapies. However, such agents could not be employed as alternative drugs for antimicrobials such as metronidazole and clarithromycin as dual therapies plus any mucoprotective agents were still unacceptable for the treatment of H pylori infection[14,22,26]. On the other hand, Hojo et al[14], could not validate the positive effect of mucoprotective agents in triple therapies. While this lack of additive efficacy may be due to high eradication rates already provided by triple therapy regimens, most trials were not randomized and the sample sizes were limited. Thus, we sought to evaluate the efficacy of sofalcone or polaprezinc when combined with the new triple therapy. To our knowledge, this is the first prospective, randomized and controlled trial undertaken to determine which of the two mucoprotective agents produces better H pylori eradication.
Sofalcone is a type of flavonoid and a synthetic derivative of sophoradine isolated from the root of the Chinese medicinal plant Sophora subprostrata[32]. Besides its mucosal protective action, sofalcone has a direct bactericidal effect on H pylori, with a minimum inhibitory concentration of 55-222 μmol/L, anti-urease activity and reduces the adhesion of this organism to gastric epithelial cells[18,19]. Polaprezinc is an insoluble chelate compound consisting of a zinc ion and L-carnosine and exerts potent mucoprotective activities[33]. It also inhibits the growth of H pylori, in addition to its urease activity and adhesion to gastric mucin[17,25]. Thus, we expected additive effects of the two mucoprotective drugs in the original proton pump inhibitor-based triple therapy. This was the case in the inclusion of sofalcone, but not polaprezinc. A 7-d course of quadruple therapy consisting of sofalcone, rabeprazole, amoxicillin and clarithromycin demonstrated satisfactory treatment outcome, H pylori eradication rate being not less than 94% on the PP basis. On the other hand, the co-prescription of polaprezinc did not improve the cure rate, which was comparable to the existing rabeprazole-amoxicillin-clarithromycin regimen.
Sakaki et al[24], reported that 7-d omeprazole-amoxicillin-clarithromycin combination therapy yielded satisfactory results by the addition of sofalcone. Moreover, adding this drug improved the eradication rate in dual therapy with lansoprazole and amoxicillin[34]. Kodama et al[23], reported that combination therapy of clarithromycin and sofalcone yield 69.2% of eradication rate without the incorporation of anti-secretory drug. Although the study designs were non-randomized and the sample sizes were not large enough to find any significant differences, it is of clinical importance that sofalcone may possess the ability to latently increase the efficacy in H pylori eradication.
In contrast to our study, the addition of polaprezinc to triple therapy with lansoprazole, amoxicillin and clarithromycin significantly improved the cure rate of H pylori in a randomized controlled trial[25]. Kuwayama et al[35] reported that this agent in combination with low dose metronidazole (750 mg/d) and amoxicillin (750 mg/d) produced a 100% H pylori eradication. The exact reason for this discrepancy remains unknown, but many factors may affect eradication efficacy such as physical structure of the patient, smoking habits, compliance in taking the therapeutic drugs, genetic predisposition of cytochrome p450 2C19, which metabolizes proton pump inhibitors, and frequency of strains resistant to antimicrobials[9-13,36,37]. In the present study, there were no significant differences in the baseline characteristics among the trial arms. The incidence of adverse events was comparable among the three treatment groups, affecting approximately 20% of patients, which is similar to previous data[28-30]. These adverse events were generally mild, causing discontinuation of therapy in only one patient. Thus, each treatment regimen was well tolerated, leading to excellent compliance in the current study. In addition, the action of rabeprazole is known to be less affected by genetic polymorphisms of the metabolic enzyme[38]. In this study, susceptibility of H pylori to antibiotics was not assessed, although we did endeavor to minimize the risk of antibiotic resistance by excluding patients who had taken medications, effective against the organism. However, Hoshiya et al[11], reported that based on the current wide use of clarithromycin, no less than 12.5% of their H pylori infected patients showed primary resistance to this agent. Clarithromycin resistance has been considered a key factor in determining the outcome of anti-H pylori therapies[10,12,13,28], and it might influence treatment results of the present eradication regimens incorporating this drug. Further studies should be conducted to determine the efficacy of mucoprotective agents in treating clarithromycin-resistant H pylori.
In conclusion, our results indicated that sofalcone provides a significant additive effect in the eradication of H pylori infection, when combined with rabeprazole, amoxicillin and clarithromycin. In contrast, polaprezinc inclusion did not improve treatment outcome of the original triple therapy. Each treatment arm yielded equally good acceptability and compliance. In clinical practice, further work should be conducted to identify the most effective mucoprotective agents with anti-H pylori activities when combined with existing eradication regimens.
Pounder RE. New developments in Helicobacter pylori eradication therapy.Scand J Gastroenterol Suppl. 1997;223:43-45.
[PubMed] [DOI][Cited in This Article: ]
Ducóns JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollón F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.Aliment Pharmacol Ther. 1999;13:775-780.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 75][Cited by in F6Publishing: 76][Article Influence: 3.0][Reference Citation Analysis (0)]
Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.Dig Dis Sci. 2001;46:2445-2450.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 29][Cited by in F6Publishing: 28][Article Influence: 1.2][Reference Citation Analysis (0)]
Hoshiya S, Watanabe K, Tokunaga K, Tanaka A, Ninomiya H, Shingaki M, Itoh T, Saito S, Ishida H, Takahashi S. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.J Gastroenterol. 2000;35:10-14.
[PubMed] [DOI][Cited in This Article: ]
Hayashi S, Sugiyama T, Amano K, Isogai H, Isogai E, Aihara M, Kikuchi M, Asaka M, Yokota K, Oguma K. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells.Antimicrob Agents Chemother. 1998;42:1895-1899.
[PubMed] [DOI][Cited in This Article: ]
Sunairi M, Tanaka N, Kuwayama H, Nakajima M. Effect of Z-103, a new antiulcer agent, on Helicobacter pylori-antimicrobial, antiurease, and antiadhesive activities.Jpn Pharmacol Ther. 1994;22:31-35.
[PubMed] [DOI][Cited in This Article: ]
Sunairi M, Watanabe K, Suzuki T, Tanaka N, Kuwayama H, Nakajima M. Effects of anti-ulcer agents on antibiotic activity against Helicobacter pylori.Eur J Gastroenterol Hepatol. 1994;6 Suppl 1:S121-S124.
[PubMed] [DOI][Cited in This Article: ]
Slomiany BL, Piotrowski J, Slomiany A. Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide.Biochem Mol Biol Int. 1997;42:155-161.
[PubMed] [DOI][Cited in This Article: ]
Kodama R, Fujioka T, Fujiyama K, Kawasaki H, Kubota T, Nasu M. Combination therapy with clarithromycin and sofalcone for eradication of Helicobacter pylori.Eur J Gastroenterol Hepatol. 1994;6 Suppl 1:S125-S128.
[PubMed] [DOI][Cited in This Article: ]
Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, Nakahara A, Mutoh H, Tanaka N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.Aliment Pharmacol Ther. 1999;13:483-487.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 44][Cited by in F6Publishing: 43][Article Influence: 1.7][Reference Citation Analysis (0)]
Isomoto H, Inoue K, Furusu H, Nishiyama H, Shikuwa S, Omagari K, Mizuta Y, Murase K, Murata I, Kohno S. Lafutidine, a novel histamine H2-receptor antagonist, versus lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.Helicobacter. 2003;8:111-119.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 24][Cited by in F6Publishing: 25][Article Influence: 1.2][Reference Citation Analysis (0)]
Isomoto H, Inoue K, Furusu H, Enjoji A, Fujimoto C, Yamakawa M, Hirakata Y, Omagari K, Mizuta Y, Murase K. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.Aliment Pharmacol Ther. 2003;18:101-107.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 46][Cited by in F6Publishing: 46][Article Influence: 2.2][Reference Citation Analysis (0)]
Isomoto H, Inoue K, Mizuta Y, Nakazato M, Kanazawa Y, Nishiyama H, Ohara H, Urata M, Omagari K, Miyazaki M. Validation of endoscopic 13C-urea breath test with nondispersive infrared spectrometric analysis in the management of Helicobacter pylori infection.Hepatogastroenterology. 2003;50:422-425.
[PubMed] [DOI][Cited in This Article: ]
Kuwayama H. Zinc compound is a novel, highly effective triple therapy for eradication of Helicobacter pylori.Gastroenterology. 1995;108:A138.
[PubMed] [DOI][Cited in This Article: ]
Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.Clin Pharmacol Ther. 2001;69:158-168.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 191][Cited by in F6Publishing: 209][Article Influence: 9.1][Reference Citation Analysis (0)]
Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.J Gastroenterol Hepatol. 2001;16:723-728.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 50][Cited by in F6Publishing: 51][Article Influence: 2.2][Reference Citation Analysis (0)]
Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status.Clin Pharmacol Ther. 1995;58:143-154.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 106][Cited by in F6Publishing: 109][Article Influence: 3.8][Reference Citation Analysis (0)]
